Mechanisms for the Negative Effects of Internalized HIV-Related Stigma on Antiretroviral Therapy Adherence in Women: The Mediating Roles of Social Isolation and Depression by Turan, Bulent et al.
EPIDEMIOLOGY AND PREVENTION
Mechanisms for the Negative Effects of Internalized
HIV-Related Stigma on Antiretroviral Therapy Adherence
in Women: The Mediating Roles of Social Isolation
and Depression
Bulent Turan, PhD,* Whitney Smith, MPH,† Mardge H. Cohen, MD,‡ Tracey E. Wilson, PhD,§
Adaora A. Adimora, MD,k Daniel Merenstein, MD,¶ Adebola Adedimeji, PhD, MPH, MBA,#
Eryka L. Wentz,** Antonina G. Foster, NP, MSN, MPH,†† Lisa Metsch, PhD,‡‡
Phyllis C. Tien, MD,§§ Sheri D. Weiser, MD, MPH,kk and Janet M. Turan, PhD, MPH†
Background: Internalization of HIV-related stigma may inhibit
a person’s ability to manage HIV disease through adherence to
treatment regimens. Studies, mainly with white men, have suggested
an association between internalized stigma and suboptimal adher-
ence to antiretroviral therapy (ART). However, there is a scarcity of
research with women of different racial/ethnic backgrounds and on
mediating mechanisms in the association between internalized
stigma and ART adherence.
Methods: The Women’s Interagency HIV Study (WIHS) is
a multicenter cohort study. Women living with HIV complete
interviewer-administered questionnaires semiannually. Cross-
sectional analyses for the current article included 1168 women on
ART for whom data on medication adherence were available from
their last study visit between April 2013 and March 2014, when the
internalized stigma measure was initially introduced.
Results: The association between internalized stigma and self-
reported suboptimal ART adherence was significant for those in
racial/ethnic minority groups (AOR = 0.69, P = 0.009, 95% CI:
0.52 to 0.91), but not for non-Hispanic whites (AOR = 2.15, P =
0.19, 95% CI: 0.69 to 6.73). Depressive symptoms, loneliness, and
low perceived social support mediated the association between
internalized stigma and suboptimal adherence in the whole
sample, as well as in the subsample of minority participants. In
serial mediation models, internalized stigma predicted less-
perceived social support (or higher loneliness), which in turn
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predicted more depressive symptoms, which in turn predicted
suboptimal medication adherence.
Conclusions: Findings suggest that interconnected psychosocial
mechanisms affect ART adherence, and that improvements in
adherence may require multifaceted interventions addressing both
mental health and interpersonal factors, especially for minority women.
Key Words: adherence, stigma, depression, social support, loneliness
(J Acquir Immune Defic Syndr 2016;72:198–205)
INTRODUCTION
Despite the importance of HIV medication adherence for
effective treatment of HIV,1 population-based estimates in the
United States (US) indicate suboptimal levels of adherence to
antiretroviral therapy (ART).2–4 An increasing body of literature
from a variety of geographic and cultural settings suggests that
HIV-related stigma is a psychosocial factor negatively associated
with HIV medication adherence.5,6 Several dimensions of HIV-
related stigma have been explored within this context, including
enacted stigma (past experiences of discrimination) and percep-
tion of stigmatization in the community.7–9 Internalization of
these stigmas, or acceptance of stigmatizing beliefs that are
present in the community—and feelings of shame and lower
self-worth as a consequence—may be the crucial factor in the
stigma–adherence association.10–13 Psychosocial consequences
of HIV-related internalized stigma (ie, self-imposed exclusion,
avoidance, fears of rejection, social withdrawal, and depression)
are hypothesized to play a major role in inhibiting a person’s
ability to adhere to HIV treatment.11,12,14,15
Longitudinal studies in resource-limited settings in
Uganda have suggested that internalized stigma predicts
decreased levels of perceived social support and separately
increase in depressive symptom severity.16,17 Research also
suggests that loneliness and lack of perceived social support
are associated with depressive symptoms among persons
living with HIV.18,19 Furthermore, meta-analyses and system-
atic reviews also support the notion that internalized HIV-
related stigma,6 lack of social support,20 and depressive
symptoms21 predict suboptimal ART adherence.
Despite the mounting evidence for the negative effects of
internalized HIV stigma, few US studies have investigated
whether loneliness, social support, depression, or related
psychosocial factors operate as mediating mechanisms for the
negative effects of internalized HIV stigma on medication
adherence. It is important for the field of HIV research to
understand why or how internalized stigma leads to nonoptimal
adherence.22 At the present time, only a few studies explored
mediating mechanisms in this relationship in the USA.15,23–25
Rao et al reported that the effect of internalized and enacted
stigma on medication adherence is mediated by depression.
Sayles et al reported an indirect effect between a multidimen-
sional measure of internalized stigma and medication adherence
that was mediated by mental health. Findings by DiIorio et al
suggested that the relationship between stigma and adherence is
mediated by self-efficacy and depression. Helms et al15 reported
that interpersonal worries mediated the effect of internalized
stigma on adherence.
However, studies examining depression used HIV
stigma scales assessing internalized stigma in combination
with other dimensions of stigma (eg, perceptions of stigma in
the community, disclosure concerns, enacted stigma).
Although internal and external stigma are intrinsically
linked,14 internalized stigma is acceptance that the external
stigma is justified and applies to the self, making people
living with HIV feel that they have a tarnished character. The
other dimensions of stigma, on the other hand, typically
involve interpersonal experiences and perceptions of other
people’s attitudes. Internalized stigma appears to operate
differently from other dimensions of HIV stigma on indica-
tors of affective and behavioral health and well-being.12 Thus,
internalization of stigma may differentially predict depressive
symptoms and adherence behavior as compared to other
dimensions of stigma. Research in this area may develop
a theoretical understanding of these relationships by distin-
guishing between pure internalized stigma scales and other
dimensions of stigma. Furthermore, the existing literature has
not yet elucidated whether and how multiple psychosocial
constructs may work together to affect the relationship
between internalized stigma and adherence in a single model.
Additionally, given epidemiologic reports that depres-
sion is more prevalent among women than men26,27 and that
depressive symptoms are related to neighborhood racial/
ethnic composition and racial discrimination,28,29 it is impor-
tant to identify whether these factors have similar consequen-
ces for adherence in samples not consisting of predominantly
male25 and Caucasian samples of patients.23 Empirical
evidence also suggests that there are race and gender
disparities in the likelihood of receiving social support and
in the effects of social support on health.30–32 Moreover, black
and other racial/ethnic minority women are disproportionately
affected by HIV infection in the USA,33 and the burden of
HIV among minorities is exacerbated by disparities in levels
of ART adherence by race/ethnicity and gender.3,34,35 There-
fore, potential predictors of adherence may operate differently
within a more diverse sample.
The purpose of the present study was to test whether
social isolation (loneliness and lack of social support) and
depressive symptoms mediate the relationship between
internalized stigma and HIV medication nonadherence in
a large sample of racially diverse women living with HIV
across the USA. We also examined whether these associ-
ations differ by race. Given that several separate studies
provided support for the theoretically plausible links
between internalized stigma and higher social isolation;
higher social isolation and depressive symptoms; and
depressive symptoms and ART non-adherence; we hypoth-
esized a serial mediation model: internalized stigma /
higher social isolation (higher loneliness or lower social
support) / depressive symptoms / ART nonadherence.
This model posits a chain effect of internalized stigma on
nonadherence sequentially through loneliness (and lower
social support) and higher depressive symptoms: Internal-
ized stigma may lead to social isolation (a potential
interpersonal manifestation of feelings of lower self-
value), which may lead to depressive symptoms that may
subsequently be associated with nonoptimal adherence.
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METHODS
Participants and Procedures
Participants were women living with HIV enrolled in
the Women’s Interagency HIV Study (WIHS), a multicenter
longitudinal cohort study.36,37 As part of this ongoing cohort
study, women living with HIV complete detailed interviewer-
administered questionnaires, physical examinations, and
specimen collection semiannually. Analyses for the current
article included 1168 women currently on ART for whom
data on medication adherence were available from their last
study visit between April 2013 and March 2014 (which
excludes 149 women from the analyses), when a measure of
internalized stigma was initially added to the battery of
measures. Data were collected from 9 WIHS sites in various
regions of the United States–San Francisco/Bay Area, CA;
Bronx/Manhattan, NY; Brooklyn, NY; Washington, DC;
Chicago, IL; Atlanta, GA; Chapel Hill, NC; Miami, FL;
and Birmingham, AL/Jackson, MS. Participants provided
written informed consent and were compensated for partic-
ipation. This protocol was approved by the Institutional
Review Board at each study site’s institution and by the
WIHS Executive Committee. The procedures followed were
in accordance with the ethical standards of the responsible
committee on human experimentation and with the Helsinki
Declaration of 1975, as revised in 2000.
Measures
Adherence
HIV medication adherence was assessed by self-report
of how often participants took their HIV medication as
prescribed over the past 6 months (1 = 100% of the time;
2 = 95–99% of the time; 3 = 75–94% of the time; 4 = ,75%
of the time; 5 = I haven’t taken any of my prescribed
medications). Self-report measures of ART adherence have
exhibited validity and reliability as a marker of clinical
impact.38–40 A 95% ART adherence rate has been used as
the cutoff for optimal versus suboptimal adherence in pre-
vious studies.41,42 Thus, we created a single variable,
dichotomized at 95% or higher versus lower than 95%.
Internalized HIV-Related Stigma
Internalized HIV-related stigma was assessed with the
negative self-image subscale of the revised HIV Stigma
Scale43 adapted from Berger et al.44 This subscale includes
7 items rated on a 4-point scale (strongly disagree to strongly
agree). A sample item is “I feel I’m not as good as others
because I have HIV/AIDS”. This scale showed high internal
consistency and test–retest reliability in previous studies.45,46
Cronbach’s alpha reliability coefficient for the 7-item sub-
scale was 0.91 in the current sample.
Depressive Symptoms
The 20-item Center for Epidemiological Studies
Depression (CES-D) scale47 is used to assess depressive
symptoms in the WIHS. Response options range from 0 to 3
(0 = Rarely or None of the Time, 3 = Most or Almost All the
Time). Depressive symptoms, as measured by the CES-D,
have been shown to predict adherence in previous stud-
ies.48,49 The sum of the 20 items was used to assess
depressive symptoms. The CES-D shows strong reliability
in other literature,48,49 and in the present sample, Cron-
bach’s alpha was 0.91.
Social Isolation (Social Support and Loneliness)
A shortened 15-item version of the MOS Social
Support Survey50 was used to assess social support. The
rating scale ranged from 1 (None of the time) to 5 (All of the
time), where higher scores indicate more social support. The
Cronbach’s alpha was 0.97 in the current study. A shortened
3-item version of the R-UCLA Loneliness Scale51 was used to
assess loneliness. The rating scale ranged from 1 (Hardly
ever) to 3 (Often), where higher scores indicate more social
isolation. The R-UCLA Loneliness Scale has evidence of
moderate-to-high reliability from other studies.52,53 Cron-
bach’s alpha in the current sample was 0.85.
Data Analyses
We used descriptive statistics to examine the charac-
teristics of the sample. To examine predictors of adherence,
logistic regression analysis was conducted. The predictors
were internalized stigma and covariates that previous
research identified as important when examining stigma–
adherence associations: race, age, time on ART, injected
and noninjected drug use, income, and education. Adjusted
odds ratios (AOR) controlling for these covariates were
reported. A mediation model was used to test whether the
association between internalized stigma and HIV medica-
tion adherence could be explained by depressive symptoms,
social support, and loneliness using the mediation analysis
with the bootstrap method for dichotomous outcomes
developed by Hayes.54 Serial mediation analyses examined
the effects of internalized stigma on adherence through the
pathways of a series of mediators.54 These mediation
analyses test the indirect effects of a predictor variable on
outcomes through the mediator(s). We also conducted
sensitivity analyses using medication adherence as a contin-
uous dependent variable in multiple regression models. In
these analyses, bootstrapping was used to accommodate the
non-normal distribution of the adherence variable. All
analyses were performed using SPSS (version 20).
RESULTS
Demographic and patient characteristics of the 1168
study participants are presented in Table 1. Over 88% of the
participants were from racial/ethnic minority groups (blacks,
Hispanics, and others), whereas non-Hispanic whites com-
prised only 12% of the sample. Given this distribution and the
focus of the present study on marginalized minority groups in
the USA, we used a dichotomized race variable in our
analyses to compare non-Hispanic whites with all other racial/
ethnic groups (Results were very similar when the 4-category
race variable was used instead of the dichotomous race
variable to examine the effect of stigma on adherence). The
logistic regression models revealed that internalized HIV
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stigma was a significant predictor of nonoptimal adherence
(AOR = 0.76, P = 0.042, 95% CI: 0.58 to 0.99). In this
analysis, income, education, and injection drug use were not
significant predictors (all P values .0.24), whereas being
non-Hispanic white, of older age, having less time on ART,
and not using noninjection drugs predicted better adherence
(all P values ,0.02). When we added the interaction between
internalized stigma and race, the interaction term was also
a significant predictor of adherence (AOR = 3.38, P = 0.026,
95% CI: 1.16 to 9.88). Therefore, logistic regression analyses
were repeated for each race category separately. For the
smaller sample of non-Hispanic whites, the effect was:
AOR = 2.15, P = 0.188, 95% CI: 0.69 to 6.73. For women
in racial/ethnic minority groups, the effect of internalized
stigma on worse adherence was: AOR = 0.69, P = 0.009, 95%
CI: 0.52 to 0.91. Based on this regression equation, we
calculated the predicted probability for optimal adherence for
a person who has an average level (ie, equal to the sample
mean) of internalized stigma (and average levels on all
covariates), which yielded a predicted probability of 0.61.
In comparison, the predicted probability of optimal adherence
for a person whose internalized stigma is one point lower than
the sample mean was 0.66.
Therefore, we examined the mediation hypotheses for
the racial/ethnic minority group only (Results were very
similar (with significant indirect effects for all mediation
analyses) when analyses were conducted for the whole
sample instead). In this subsample, logistic regression
analysis revealed that internalized stigma was no longer
a significant predictor of adherence when depression was
added to the model (AOR = 0.89, P = 0.464, 95% CI: 0.66 to
1.21). Depression was a significant predictor of worse
adherence in this model (AOR = 0.96, P , 0.001, 95% CI:
0.95 to 0.98). The mediation analysis yielded a significant
indirect effect of internalized stigma on worse adherence
through depression (B = 20.24, SE = 0.06, 95% CI: 20.37 to
20.14). Thus, the effect of internalized stigma on adherence
was mediated by depression as demonstrated in Figure 1.
Some of the items in the depression scale concern low
self-worth [eg, “I felt I was just as good as other people
(reversed)”] and may inflate associations with internalized
stigma. Therefore, we also tested the mediation effect
among minority women using the sum of only those items
in the depression scale that are unrelated to low self-worth,
which again revealed a significant indirect effect of internal-
ized stigma on adherence through the pathway of depression
(B = 20.21, SE = 0.05, 95% CI: 20.32 to 20.11). Social
support was also a significant mediator of the effect of
internalized stigma on lower adherence with a significant
indirect effect (B = 20.098, SE = 0.042, 95% CI: 20.195 to
20.030). Finally, loneliness was also a significant mediator of
the effect of internalized stigma on lower adherence with
a significant indirect effect (B = 20.12, SE = 0.05, 95% CI:
20.23 to 0.02).
As seen in Figure 2, for minority women serial
mediation analysis also yielded a significant indirect effect of
stigma on lower ART adherence through less social support
and through higher depression (B = 20.03, SE = 0.01,




Non-Hispanic white 139 (11.9)
Non-Hispanic black 788 (67.5)
Hispanic 200 (17.1)
Other 41 (3.5)
Noninjected drug use 256 (22.0)
Injection drug use 10 (0.9)
Adherence (,95%) 201 (17.2)
Variable Mean (SD) Possible Range
Age (yrs) 49.12 (8.59) —
Education 4.09 (1.05) 1–7
Income 3.37 (2.14) 1–8
Years on ART 11.08 (6.30) —
Internalized HIV-related stigma 1.74 (0.62) 1–4
Depressive symptoms 12.23 (11.27) 0–60
Social support 4.01 (1.02) 1–5
Loneliness 1.40 (0.59) 1–3
FIGURE 1. Depression mediates the effect of
internalized HIV-related stigma on suboptimal
medication adherence for racial/ethnic minority
groups (ie, non-whites). n = 1029.
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95% CI: 20.06 to 20.01) (The serial mediation also yielded
a significant serial indirect effect when the mean of the items
in the depression scale that are unrelated to low self-worth were
used). Figure 2 depicts the relationships between these variables,
illustrating our findings that internalized stigma predicted less
social support, which in turn predicted more depressive
symptoms, which in turn predicted poorer medication adher-
ence. Results were very similar when loneliness was used
instead of social support in the analyses. The serial mediation
also yielded a significant indirect effect of stigma on lower ART
adherence through higher loneliness and through higher depres-
sion (B = 20.07, SE = 0.02, 95% CI: 20.12 to 20.02).
Sensitivity analyses using adherence as a continuous dependent
variable (using bootstrapping) are presented in Supplemental
Digital Content 1, http://links.lww.com/QAI/A788. All of these
analyses yielded results very similar to our original analyses
using dichotomized adherence as the dependent variable.
DISCUSSION
The current study contributes to the extant literature by
examining the mediating effect of social support or loneliness
and subsequently, of depression, in the association between
internalized HIV stigma and HIV medication adherence in
women. The results indicate that HIV-related internalized
stigma has an indirect and negative effect on adherence for
women living with HIV mediated by social support or
loneliness and depression. Initial analyses suggested that
depressive symptoms, low social support, and loneliness each
individually mediated the relationship between internalized
stigma and poorer adherence. In further analyses, we found
that less social support and separately higher loneliness
operate through higher depression to mediate the relationship
between internalized HIV stigma and lower adherence. These
results were obtained for the whole sample, but the effect of
internalized stigma on ART adherence was stronger for
women in racial/ethnic minority groups than for non-
Hispanic white women. This finding may contribute to our
understanding of why non-white women living with HIV
have lower adherence rates and worse outcomes than white
women.55,56
The findings of the present study have important
theoretical and practical implications. Our finding that
depressive symptoms explain the relationship between
HIV-related internalized stigma and medication adherence
for women living with HIV support similar previous
results from smaller samples consisting of mostly white
men.23,25 Additional mechanisms through which stigma
affects use of ART had yet to be elucidated, however. The
current study indicated that less social support and higher
loneliness may intensify depressive symptoms, which in
turn predict poorer medication adherence. In general, this
is in concordance with previous research suggesting that
access to social support promotes ART adherence among
people living with HIV by enabling them to overcome
barriers to effective treatment.6,9
At this point in stigma research, it is very important to
understand in a more nuanced manner the ways in which
stigma affects the lives of people living with HIV.22 The
experience of internalizing stigma leads to self-imposed
isolation and exclusion from social situations,17,57 which
may lead to reduced self-efficacy and depressive symptoms
such as disempowerment, helplessness, inability to concen-
trate, and feelings of negativity and anguish.14,47 It is likely
that these symptoms make it more difficult to adhere to ART.
The presence of depressive symptoms may even affect one’s
desire for self-preservation and thus contribute to the
tendency to neglect self-care needs.48 It is possible that these
relationships also operate in a bidirectional manner. Existing
literature suggests that effective ART adherence is associated
with decreased depressive symptom severity.21 Depression
could lead to lower social support, given that research
suggests that nondepressed individuals show patterns of
negative affect and a tendency to socially reject depressed
individuals after a social interaction with them.58 Further-
more, lower social support could lead to more internalized
stigma, given that persons living with HIV often draw on
social support to minimize the harmful influences of stigma.6
FIGURE 2. Serial mediation model in the associ-
ation between internalized HIV-related stigma and
suboptimal medication adherence for racial/
ethnic minority groups (ie, non-whites). n = 1029.
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An understanding of these interconnected factors
affecting HIV medication adherence provides insight into
what conditions/situations can potentially be targeted
through interventions. Our findings contribute to the exist-
ing literature by implicating multiple stages at which we
may be able to intervene to improve HIV-related health
outcomes (ie, 1—internalization of stigma; 2—lack of
social support or loneliness; and 3—depression). Programs
aiming to improve ART adherence for women living with
HIV may benefit from targeted strategies to address all 3 of
these factors. Some depression treatment interventions have
yielded promising results in improving adherence,59,60 but
others resulted in no effect.61,62 Future intervention studies
should examine the effectiveness of programs that seek to
address depression, internalized stigma, and lack of social
support simultaneously.
The strengths of the current study include the use of
detailed and reliable measurement tools—including a multi-
item measure of internalized stigma specific to HIV that has
shown good evidence of construct and discriminant val-
idity43—and measures of social support and loneliness not
previously used to explore these relationships. Compared to
previous studies,23,49 our study included a larger sample of
racial/ethnic minority participants, who may be more
representative of the population with least engagement in
HIV care,55 the highest risk of HIV mortality in the USA,56
and according to the present results, may be more strongly
affected by stigma. Furthermore, our sample was comprised
of women living with HIV who represent multiple geo-
graphically diverse sites within the USA, rather than a single
site, which may also enable greater generalizability. Finally,
we used mediation modeling using bootstrapping to exam-
ine the interconnected relationships, which allowed us to
explore the interpersonal and intrapersonal mechanisms in
the association between internalized stigma and HIV
medication adherence.
Limitations of the study include the use of cross-
sectional data, which prevents us from inferring causal
relationships. However, our study findings are consistent
with previous research and theory, which suggests that
constructs similar to internalized stigma, such as self-
esteem, lead to depression longitudinally, but that prior
depression does not predict later self-esteem.63 Our findings
also lend theoretical support to causal models of the relation-
ships between internalized stigma and social support,17 and
depression separately,16 found in longitudinal designs in
Uganda. Future studies using longitudinal designs or inter-
ventions are required to further elucidate causal relationships
between social support and depressive symptoms, as well as
depressive symptoms and adherence, and to confirm our
hypothesized directionality.
An additional limitation is that there may be unob-
served variables that are associated with both the mediators
and the outcome, which may lead to biased results. We
controlled for some of the variables that are known to
predict ART adherence. However, there may be other
variables not measured in our study that are associated
with both social support (or loneliness) and adherence. It is
also possible that unobserved potential mediator variables
exist that are associated with our observed mediators and
confound the mediation. These difficulties in interpretation
are inherent in every mediation analysis because it is not
possible to experimentally manipulate both the predictor
and the mediator in a single study. Future research
examining other theoretically relevant variables and using
longitudinal designs may contribute to a better understand-
ing of mediating mechanisms by providing analyses from
different perspectives.
We examined predictors of adherence using a self-
reported measure of adherence, which may be subject to
response bias. Nevertheless, an extensive literature review
indicated that brief self-reported measures of ART adher-
ence such as that used in the current study are robust and
reliable.38 Future studies examining associations with
ART adherence may consider use of objective markers
of adherence, such as antiretroviral concentrations in
hair samples.
Our findings suggest that internalized stigma and poor
adherence are indirectly related. This relationship is mediated
by lack of social support, loneliness, and depressive symp-
toms. Further research can use these findings to develop
multifaceted interventions to help women living with HIV to
obtain mental health treatment and/or build skills to deal with
these social and psychological factors, and evaluate the
impact of such interventions on adherence.
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